

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No: 10/577,840
Applicant: Pere Joan Cardona Iglesias et al.
Filed: February 1, 2007
Title: IMMUNOTHERAPEUTIC AGENT FOR THE COMBINED TREATMENT OF
TUBERCULOSIS IN ASSOCIATION WITH OTHER DRUGS
TC/A.U.: 1633
Examiner: Fereydoun Ghotb Sajjadi
Confirmation No.: 9930
Docket No.: TJA-139US

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. § 1.56, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO/SB/08a and PTO/SB/08b form submitted herewith. A copy of each reference listed on the PTO/SB/08a and PTO/SB/08b form, other than U.S. patents, is enclosed.

Although the Information submitted herewith may be "material" to the Examiner's consideration of the subject application, this submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention.


In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

Reference ES 2 231 037 is not in the English language, but corresponding English language U.S. Patent Application Publication US 2007/026950 A1 is submitted herewith.

More than three months have elapsed since the filing of the above-referenced application and a first (non-Final) Official Action has been received. No Final Action or Notice of Allowance has yet been received and it is presumed that none has yet been mailed. Accordingly, the required fee set forth in 37 C.F.R. § 1.17(p) is provided herewith.

Respectfully submitted,

RatnerPrestia



Jacques L. Efkwicz, Reg. No. 41,738
Attorney for Applicants

JLE/kpc

Enclosures: PTO/SB/08a and PTO/SB/08b form
(8) References

Dated: May 1, 2009

P.O. Box 980
Valley Forge, PA 19482
(610) 407-0700

The Director is hereby authorized to charge
or credit Deposit Account No. **18-0350** for
any additional fees, or any underpayment or
credit for overpayment in connection
herewith.